ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
17.902,69
-0,11%
S&P 500
5.038,49
0,40%
Dow Jones
38.073,95
0,45%
Euro vs US Dollar
1,06857
-0,30%
Bitcoin
59.080,53
1,45%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Tarsus Pharmaceuticals Inc (TARS)

  7. Tarsus Pharmaceuticals Inc (TARS) News

TARS Tarsus Pharmaceuticals Inc

32,62
0,13 (0,40%)
Zuletzt aktualisiert: 16:47:16
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Tarsus Pharmaceuticals Inc TARS NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,13 0,40% 32,62 16:47:16
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
32,31 32,02 33,34 32,49
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
01.5.202423:00GLOBETarsus to Report First Quarter 2024 Financial Results on..
23.4.202414:30GLOBETarsus Strengthens Financial Position and Refinances..
11.3.202422:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11.3.202422:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11.3.202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11.3.202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202422:30GLOBETarsus to Participate at Upcoming Investor Conferences
05.3.202422:09EDGAR2Form 8-K - Current report
05.3.202414:30GLOBETarsus Introduces “Mite Party” Campaign for XDEMVY®..
01.3.202423:26EDGAR2Form 8-K - Current report
01.3.202423:17EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
01.3.202406:07GLOBETarsus Announces Pricing of $100.0 Million Public Offering
29.2.202423:08EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29.2.202422:37GLOBETarsus Announces Proposed $100.0 Million Public Offering
29.2.202422:32EDGAR2Form S-3ASR - Automatic shelf registration statement of..
27.2.202422:22EDGAR2Form S-8 - Securities to be offered to employees in employee..
27.2.202422:02EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27.2.202412:00GLOBETarsus Reports Strong Fourth Quarter and Full-Year 2023..
22.2.202414:00GLOBETarsus Announces Positive Topline Results from Carpo, a..
20.2.202423:00GLOBETarsus to Report Fourth Quarter and Full Year 2023 Financial..
31.1.202423:00GLOBETarsus to Participate in Fireside Chat at the Sixth Annual..
30.1.202422:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.1.202423:05EDGAR2Form SC 13G - Statement of acquisition of beneficial..
18.1.202422:30EDGAR2Form 8-K - Current report
08.1.202415:00EDGAR2Form 8-K - Current report
29.12.202323:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.12.202322:23EDGAR2Form 144 - Report of proposed sale of securities
22.12.202323:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.12.202322:49EDGAR2Form 144 - Report of proposed sale of securities
20.12.202300:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11.12.202315:01EDGAR2Form 8-K - Current report
11.12.202314:00GLOBETarsus Announces Positive Topline Results from the Ersa..
01.12.202322:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.12.202322:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30.11.202322:35EDGAR2Form 144 - Report of proposed sale of securities
30.11.202322:15EDGAR2Form 144 - Report of proposed sale of securities
22.11.202306:15EDGAR2Form EFFECT - Notice of Effectiveness
17.11.202322:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.11.202322:53EDGAR2Form 144 - Report of proposed sale of securities
09.11.202322:18EDGAR2Form S-3 - Registration statement under Securities Act of..
09.11.202322:05EDGAR2Form 8-K - Current report
09.11.202322:05GLOBETarsus Reports Third Quarter 2023 Financial Results and..
09.11.202322:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01.11.202323:35GLOBETarsus to Report Third Quarter 2023 Financial Results on..
20.10.202322:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18.10.202322:26EDGAR2Form 144 - Report of proposed sale of securities
22.9.202323:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.9.202322:30EDGAR2Form 144 - Report of proposed sale of securities
06.9.202314:00GLOBETarsus to Ring Nasdaq Stock Market Closing Bell in..
30.8.202322:30GLOBETarsus to Present at Upcoming Investor Conferences

Kürzlich von Ihnen besucht

NASDAQ
TARS
Tarsus Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten